We sought to ascertain which clinical characteristics including presence of exposed lesions are associated with impairment of health-related quality of life (HRQoL) in patients with psoriasis.

Methods

The EPI-PSODE study was a nationwide, multicenter, cross-sectional study conducted in Korea that included 1260 adult patients with psoriasis. In addition to clinical characteristics including presence of exposed lesions, data were collected using the Psoriatic Arthritis (PsA) Screening and Evaluation (PASE), Dermatology Life Quality Index (DLQI), MOS 36-Item Short-Form Health Survey (SF-36), Work Productivity and Activity Impairment Questionnaire Psoriasis (WPAI: PSO) and Medication Satisfaction Questionnaire (MSQ).

Results

Patients with a DLQI score > 5 (n = 990) were younger, had an earlier onset of psoriasis, scored higher on the Psoriasis Area and Severity Index (PASI), had higher body surface area (BSA) and had higher PASE scores than patients with DLQI ≤ 5 (n = 266). The group of patients with exposed lesions (n = 871) were younger and male predominance, earlier onset of psoriasis, longer disease duration, higher PASI/BSA score and a higher proportion with drinking and smoking history each than the group of patients without exposed lesions (n = 389). Presence of exposed lesions negatively influenced DLQI, 36-Item Short-Form Health Survey (SF-36) (mental component), presenteeism, total work productivity impairment and total activity impairment in the WPAI: PSO. In multiple regression model, PASI score was the only variable which was significantly associated with all HRQoL measures. Presence of exposed lesions was a significant factor affecting DLQI and SF-36 (mental).

Conclusion

The presence of exposed lesions has a negative impact on quality of life, mental health and work productivity. Therefore, effective treatments are particularly needed for psoriasis patients with exposed lesions.

References

1Schön MP, Boehncke WH. Psoriasis. N Engl J Med 2005; 352: 1899–1912.
10.1056/NEJMra041320
CAS PubMed Web of Science® Google Scholar
2Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361: 496–509.
10.1056/NEJMra0804595
CAS PubMed Web of Science® Google Scholar
3Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004; 51: 704–708.
10.1016/j.jaad.2004.04.014
PubMed Web of Science® Google Scholar
4Finlay AY. Quality of life measurement in dermatology: a practical guide. Br J Dermatol 1997; 136: 305–314.
10.1111/j.1365-2133.1997.tb14934.x
CAS PubMed Web of Science® Google Scholar
5Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–216.
10.1111/j.1365-2230.1994.tb01167.x
CAS PubMed Web of Science® Google Scholar
6Anderson RT, Rajagopalan R. Development and validation of a quality of life instrument for cutaneous diseases. J Am Acad Dermatol 1997; 37: 41–50.
10.1016/S0190-9622(97)70210-X
CAS PubMed Web of Science® Google Scholar
7Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133: 1433–1440.
10.1001/archderm.1997.03890470111018
CAS PubMed Web of Science® Google Scholar
8Mrowietz U, Kragballe K, Reich K. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1–10.
10.1007/s00403-010-1080-1
CAS PubMed Web of Science® Google Scholar
9Song HJ, Park CJ, Kim TY et al. The clinical profile of patients with psoriasis in Korea: A nationwide cross-sectional study (EPI-PSODE). Ann Dermatol 2017; 29: 462–470.
10.5021/ad.2017.29.4.462
PubMed Web of Science® Google Scholar
10Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–483.
10.1097/00005650-199206000-00002
CAS PubMed Web of Science® Google Scholar
11McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247–263.
10.1097/00005650-199303000-00006
CAS PubMed Web of Science® Google Scholar
12Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353–365.
10.2165/00019053-199304050-00006
CAS PubMed Web of Science® Google Scholar
13Vernon MK, Revicki DA, Awad AG et al. Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients. Schizophr Res 2010; 118: 271–278.
10.1016/j.schres.2010.01.021
PubMed Web of Science® Google Scholar
14Lebwohl M, Papp K, Han C et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol 2010; 162: 137–146.
10.1111/j.1365-2133.2009.09491.x
CAS PubMed Web of Science® Google Scholar
15Fernández-Torres RM, Pita-Fernández S, Fonseca E. Quality of life and related factors in a cohort of plaque-type psoriasis patients in La Coruña, Spain. Int J Dermatol 2014; 53: e507–e511.
10.1111/ijd.12294
PubMed Web of Science® Google Scholar
16Cozzani E, Borrini V, Pennella A et al. The quality of life in Italian psoriatic patients treated with biological drugs. G Ital Dermatol Venereol 2010; 145: 709–712.
CAS PubMed Web of Science® Google Scholar
17Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64(Suppl. 2): ii18–ii23; discussion ii24–25.
10.1136/ard.2004.033217
PubMed Web of Science® Google Scholar
18Singh SM, Narang T, Dogra S, Verma AK, Gupta S, Handa S. Screening for depressive disorders in outpatients with mild to moderate psoriasis: A study from North India. Indian J Dermatol Venereol Leprol 2015; 81: 148–150.
10.4103/0378-6323.152178
PubMed Web of Science® Google Scholar
19Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2016; 31: 213–220.
10.1111/jdv.14007
PubMed Web of Science® Google Scholar
20Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology 2008; 216: 260–270.
10.1159/000113150
PubMed Web of Science® Google Scholar
21Ali FM, Cueva AC, Vyas J et al. A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis. Br J Dermatol 2016; 176: 577–593.
10.1111/bjd.14788
PubMed Web of Science® Google Scholar
22Krenzer S, Radtke M, Schmitt-Rau K, Augustin M. Characterization of patient-reported outcomes in moderate to severe psoriasis. Dermatology 2011; 223: 80–86.
10.1159/000330560
PubMed Web of Science® Google Scholar
23Korman NJ, Zhao Y, Pike J, Roberts J. Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA. Clin Exp Dermatol 2016; 41: 514–521.
10.1111/ced.12841
CAS PubMed Web of Science® Google Scholar
24Tsai TF, Song M, Shen YK et al. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial. J Drugs Dermatol 2012; 11: 943–949.
CAS PubMed Web of Science® Google Scholar
25Guenther L, Han C, Szapary P et al. Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials. J Eur Acad Dermatol Venereol 2011; 25: 851–857.
10.1111/j.1468-3083.2011.04082.x
CAS PubMed Web of Science® Google Scholar
26Nakagawa H, Schenkel B, Kato M, Kato T, Igarashi A, Japanese Ustekinumab Study Group. Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled phase 2/3 trial. J Dermatol 2012; 39: 761–769.
10.1111/j.1346-8138.2012.01521.x
CAS PubMed Web of Science® Google Scholar
27Bronsard V, Paul C, Prey S et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24(Suppl. 2): 17–22.
10.1111/j.1468-3083.2009.03563.x
PubMed Web of Science® Google Scholar
28Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol 2005; 125: 659–664.
10.1111/j.0022-202X.2005.23621.x
CAS PubMed Web of Science® Google Scholar
29Van den Reek JM, Zweegers J, Kievit W et al. ‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network. Br J Dermatol 2014; 171: 1189–1196.
10.1111/bjd.13087
CAS PubMed Web of Science® Google Scholar
30Petraškien≐ R, Valiukevičien≐ S, Macijauskien≐ J. Associations of the quality of life and psychoemotional state with sociodemographic factors in patients with psoriasis. Medicina (Kaunas) 2016; 52: 238–243.
10.1016/j.medici.2016.07.001
PubMed Web of Science® Google Scholar
31Lin TY, See LC, Shen YM, Liang CY, Chang HN, Lin YK. Quality of life in patients with psoriasis in northern Taiwan. Chang Gung Med J 2011; 34: 186–196.
PubMed Google Scholar
32Rosen CF, Mussani F, Chandran V, Eder L, Thavaneswaran A, Gladman DD. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology (Oxford) 2012; 51: 571–576.
10.1093/rheumatology/ker365
PubMed Web of Science® Google Scholar
33Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 2009; 160: 1040–1047.
10.1111/j.1365-2133.2008.09023.x
CAS PubMed Web of Science® Google Scholar
34Sojević Timotijević Z, Janković S, Trajković G et al. Identification of psoriatic patients at risk of high quality of life impairment. J Dermatol 2013; 40: 797–804.
10.1111/1346-8138.12201
PubMed Web of Science® Google Scholar
35 Syed Nong Chek SR. Robinson S, Mohd Affandi A, Baharum N. Clinical characteristics of patients with facial psoriasis in Malaysia. Int J Dermatol 2016; 55: 1092–1095.
10.1111/ijd.13307
PubMed Web of Science® Google Scholar
36Radtke MA, Langenbruch AK, Schäfer I, Herberger K, Reich K, Augustin M. Nail psoriasis as a severity indicator: results from the PsoReal study. Patient Relat Outcome Meas 2011; 2: 1–6.
PubMed Google Scholar
37Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol 2007; 57: 963–971.
10.1016/j.jaad.2007.07.023
PubMed Web of Science® Google Scholar

Citing Literature

Volume32, Issue9

September 2018

Pages 1499-1506

The relationship between clinical characteristics including presence of exposed lesions and health-related quality of life (HRQoL) in patients with psoriasis: analysis from the nationwide epidemiologic study for psoriasis in Korea (EPI-PSODE study)

Abstract

Background

Objective

Methods

Results

Conclusion

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

The relationship between clinical characteristics including presence of exposed lesions and health-related quality of life (HRQoL) in patients with psoriasis: analysis from the nationwide epidemiologic study for psoriasis in Korea (EPI-PSODE study)

Abstract

Background

Objective

Methods

Results

Conclusion

References

Citing Literature

References

Related

Information